Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply

Affiliations

¹ Department of Oncology and Hematology, AUSL Romagna, 48100 Ravenna, Italy. Electronic address: federico.cappuzzo@auslromagna.it.
² Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, USA.

Comment

Federico Cappuzzo et al. Lancet Oncol. 2019 Sep.

. 2019 Sep;20(9):e467.

doi: 10.1016/S1470-2045(19)30544-3.

¹ Department of Oncology and Hematology, AUSL Romagna, 48100 Ravenna, Italy. Electronic address: federico.cappuzzo@auslromagna.it.
² Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, USA.

No abstract available

Comment on

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. West H, et al. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20. Lancet Oncol. 2019. PMID: 31122901 Clinical Trial.
Chemoimmunotherapy for stage IV non-small-cell lung cancer.
Uprety D. Uprety D. Lancet Oncol. 2019 Sep;20(9):e466. doi: 10.1016/S1470-2045(19)30498-X. Lancet Oncol. 2019. PMID: 31486365 No abstract available.